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Abstract Tissue transglutaminase (tTgase) is a GTP-binding 
Ca2÷-dependent enzyme which catalyses the post-translational 
modification of proteins via e(3,-glutamyl) ysine bridges. Recent 
evidence suggests that the GTP-binding activity of tTgase may 
be important in intraceHular signalling thus explaining some of 
the diverse suggested roles for the enzyme. In the following work 
a malignant hamster fibrosarcoma (Met B) has been stably trans- 
fected with both the full length tTgase cDNA (wild type) and a 
mutant form of the cDNA whereby the active site cysteine (Cys 
277) has been replaced by serine. Expression of this mutant 
cDNA leads to a protein with GTP binding activity which is 
deficient of protein crosslinking activity. When synchronised into 
S-phase and allowed to progress through the cell cycle tTgase 
transfected clones (both mutant and wild type), when compared 
to transfected controls, show a delayed progression from S-phase 
to G2/M when analysed by flow cytometry which appears to be 
elicited by the G-protein activity of the tTgase. 
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I. Introduction 
Tissue transglutaminase (tTgase, Type II) is calcium-depend- 
ent enzyme wich catalyses the post-translational modification 
of proteins either through their crosslinking via e(~'-glutamyl) 
lysine bonds or through the incorporation of amines into pro- 
tein bound y-glutamyl groups. The tissue transglutaminase i  
ubiquitously found in mammalian tissues both in the mem- 
brane and cytosolic fractions and belongs to a larger family of 
transglutaminases which have distinct genes, structures and 
biological functions [1]. Although the cellular function of 
tTgase is still not fully understood it has been implicated in 
receptor mediated endocytosis [2] stimulus secretion coupling 
[3], programmed cell death [4] extracellular matrix organisation 
and cell adhesion [5], cell growth and proliferation [6,7] and 
tumour growth [8,9]. 
Despite these observations the correlation between tTgase 
gene expression and crosslinked proteins found in cells is not 
always apparent suggesting that the tTgase is either very tightly 
regulated within the cell or the enzyme has other functions in 
addition to or in association with its crosslinking role. In keep- 
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ing with this theory is the finding that tTgase is a GTP-binding 
protein with GTPase activity [10] and that GTP binding to the 
enzyme can inhibit its catalytic activity at physiological calcium 
levels [11]. However only recently has a biological role for 
tTgase as a functional G-protein been reported [12] whereby it 
has been shown to mediate cd-adrenergic receptor stimulation 
of phospholipase C in COS-1 cells. This ability of tTgase to 
modulate levels of intracellular messengers opens up an intrigu- 
ing scenario about the biological functions of tTgase and may 
explain some of its diverse physiological roles. 
In the following paper we have concentrated on the possible 
role of tTgase in cell growth and proliferation and its potential 
importance in tumour growth. In this respect we have investi- 
gated whether the tTgase G-protein has any regulatory role in 
the progression of the cell through the cell cycle. In order to 
differentiate Tgase crosslinking activity from its GTP-binding 
role in this process we have stably transfected a malignant 
hamster fibrosarcoma (Met B) with both the full length tTgase 
eDNA (wild type) and a mutant form of the cDNA under the 
control of a constitutive ukaryotic expression vector. In the 
mutated eDNA the active site cysteine (Cys 277) has been 
replaced by serine so that expression of this mutant eDNA in 
the tumour cells leads to a protein with GTP-binding activity 
but is deficient in protein crosslinking activity [13]. 
2. Materials and methods 
The origin and celt culture of the Met B hamster fibrosarcoma has 
been previously described [14]. Cells were grown in supplemented 
DMEM and cell numbers were monitored by direct counting using a 
haemocytometer. Viable cells were counted as those excluding Trypan 
blue. Synchronisation ofcells into early S-phase using a double xpo- 
sure to thymidine has been previously described [15]. The degree of cell 
synchrony was assessed at various times following release of thymidine 
either by flow cytometry or by incorporation of [3H]thymidine (33 
mCi/mmol Amersham International Buck., UK) into DNA as de- 
scribed earlier [15]. Flow cytometry was carried out in cells stained with 
propidium iodide using an Orthocyte bench top cytometer quipped 
with a mercury/xenon arc lamp. DNA histograms were stored and files 
reanalysed using the MULTICYCLE DNA analysis package [15]. 
Expression constructs containing the human tissue transglutaminase 
eDNA were prepared as previously described [16]. Mutation of the 
active site cysteine (Cys 277) to serine was undertaken by site directed 
mutagenesis using the Clontech Kit 'Transformer'. Site-Directed 
Mutagenesis Kit (Clontech Palo Alto, CA) based upon the Deng and 
Nickoloffmethod [17] Cys ---) Ser 277 tTgase mutant was identified and 
confirmed by automatic DNA sequencing of the full length eDNA. A 
initial transient transfections of the wild type pSG5-tTgase and the 
Cys ~ Ser-mutant pSG5-tTgase (pSG5-tTgase-M) were carried out in 
COS-1 cells using the DEAE-dextran method and both transglutami- 
nase activity and antigen levels were determined following procedures 
previously described [14]. 
Stable transfection of Met B cells with the expression constructs and 
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Fig. 1. Expression of tissue transglutaminase in transfected clones de- 
tected by Western blotting TG STD; purified guinea pig liver transglu- 
taminase, Lane 1,136; Lane 2, Clone I24; Lane 3, Clone 36; Lane 4, 
Clone 1; Lanes 5-8, pSVneo controls 14. 
the pSVneo selection plasmid was undertaken using Lipofectin as de- 
scribed by Johnson et al. [14]. Stably transfected cells were selected and 
cloned in normal growth media containing 800 U per ml G418 sulphate 
(Geneticin, Gibco Laboratories). For monitoring the expression of 
tissue transglutaminase, activity was measured in cloned cell lines by 
the [laC]putrescine incorporation i to N,N-dimethylcasein assay [18]. 
Total cellular RNA was extracted using RN azol B (Cinnex Ltd). Initial 
screening of clones carrying the mutant cDNA was undertaken by dot 
blots whereby isolated RNA was hybridised to a 1.1 kb Bal 1 deletion 
probe constructed from a full length cDNA of the human tissue 
transglutaminase as previously described [14]. Enzyme antigen was 
measured by immunoprobing Western blots with a goat anti-guinea pig 
liver transglutaminase and revealing by chemiluminescence (Amersham 
Ltd.) Guinea pig liver enzyme (Sigma Chemical Co., Poole, Dorset, 
UK) or human colon carcinoma cells (HT 29) were used as sources of 
tTgase standard. 
3. Results and discussion 
3.1. Selection of  transfected clones 
The eukaryotic expression vector pSG5 containing a 3.3 kb 
cDNA (wild type pSG5 tTgase and the Cys ~ Ser mutant, pSG5 
tTgase M) of the human endothelial cell tissue transglutami- 
nase [19] was used in these studies. Mutation of the active site 
cysteine (Cys 277) to serine of the human tTgase resulted in the 
expression of a catalytically inactive nzyme as determined by 
enzymatic assays and immunoblotting analysis of transient 
transfection experiments carried out using the DEAE-dextran 
method in COS-1 cells (data not shown). Wild type pSG5- 
tTgase and pSG5-tTgase-M (The Cys --* Ser mutant) were then 
used to express the enzyme in the highly malignant hamster 
fibrosarcoma cell line Met B. For stable clones carrying the wild 
type cDNA the previously reported Clones 1 and 36 were used 
in this study [14]. These clones carry significantly higher levels 
of tTgase activity and antigen (Table 1, Fig. 1) when compared 
to the Met B controls transfected with only the selection vector 
pSVneo. Stable clones of Met B cells carrying the pSG5 tTgase 
M and the selection vector pSVneo were obtained as described 
in Section 2. All stable clones including control clones carrying 
pSVneo alone were selected by their ability to tolerate growth 
on media containing G418. 
Assessment of tTgase antigen in homogenates of cells trans- 
fected with pSG5 tTgase M allowed the selection of 2 clones, 
124 and 136, with increased levels of tTgase antigen when com- 
pared to transfected controls (Fig. 1). These two clones con- 
tained comparable vels of tTgase antigen, when compared by 
immunoblotting to that found in wild type Clones 1 and 36 (Fig. 
1). However unlike Clones 1 and 36 the levels oftTgase activity 
in Clones 124 and 136 was comparable to that found in the 
pSVneo transfected controls (Table 1), which is in keeping with 
the expression of the mutated cDNA in these cells. In Clone 124 
a higher molecular weight form of the enzyme antigen (approx. 
120 kDa) was also detectable when Western blots were im- 
munoprobed with a goat anti-guinea pig liver antibody. Al- 
though it is difficult at this point to suggest reasons for expres- 
sion of this higher molecular weight antigen it is interesting to 
note that an inactive tTgase protein of comparable size was 
found in the original Met B cell line when cell extracts were 
fractionated by anion exchange chromatography [20]. 
3.2. Cell cycle progression studies 
Previous studies with the Met B fibrosarcoma have shown 
that these cells can be efficiently synchronised into early S- 
phase after a double exposure to thymidine such that 75-80% 
of the cell population is in early S-phase [15]. Extension of this 
procedure to the transfected clones indicated similar results 
could be obtained with each of the stable transfects when the 
cells were analysed by flow cytometry and the DNA histograms 
compared (Fig. 2). Following release of the thymidine drug cells 
progressed through S-phase into G2/M such that for control 
cell lines carrying pSVneo total loss of synchrony was apparent 
after 8 h. In contrast a comparison of the DNA histograms 
from cells transfected with the tTgase cDNA (both mutant and 
wild type) indicated that even after 8 h a large percentage of 
cells were still progressing from S-phase into G2/M. A compar- 
ison of cell cycle distribution for all the transfected clones at 
8 h after release of drug (Table 2) indicated comparability for 
each of the tTgase transfected clones (wild type and mutant 
cDNA), while the transfected control cell lines were more com- 
parable to the distribution shown for the wild type Met B cell 
line. To confirm the data shown by flow cytometry two of the 
transfected clones Clone 1 and pSVneol were further moni- 
Table 1 
Tissue transglutaminase activity in Met B and stably transfected clones 
Cell line Transglutami- 
nase activity 
(U]106 cells) 
Met B 0.14 + 0.16 
Transfected controls Met B pSVneo 1 0.18 + 0.13 
2 0.67 + 0.2 
3 0.78 + 0.39 
4 1.72 + 0.3 
Transfected with Clone 1 28.7 + 2.7 
wild type cDNA Clone 36 20.0 + 1.0 
Transfected with Clone I 24 1.04 + 0.29 
mutant cDNA Clone I 36 1.42 + 0.34 
Tissue transglutaminase activity was measured according to the proce- 
dures described in section 2. 
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Fig. 2. DNA histograms from thymidine-synchronised transfected Met B cells (A), Clone 1; (B), pSVneol; (C), Clone I24. At the time indicated in 
each figure, cells were released from thymidine blockade and analysed by flow cytometry as described in section 2. NS, non-synchronised cell 
population. 
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Table 2 
Cell cycle distribution 8 h after release of drug for Met B, Met B cells transfected with pSVneo, the wild type tTgase cDNA and the mutant cDNA 
Percentage distribution of cells at 8 h after synchronisation into early S-phase 
Cell line G] S G2]M S + GJM 
Mutant Clone 124 13.3 43.7 43 86.7 
tTgase-transfected Clone 136 24.6 24.7 50.6 75.3 
clones Wild type Clone 1 23.1 51.2 25.7 76.9 
Clone 36 23.9 35.9 40.2 76.1 
Controls pSVneo 1 62.7 18.7 18.6 37.3 
pSVneo 2 44.8 17.3 37.9 55.2 
pSVneo 3 43.8 19.4 36.9 56.3 
pSVneo 4 44.9 18.4 36.7 55.1 
Met B 56.7 23.2 20.1 43.3 
The distribution of cells in each phase of the cell cycle was calculated from DNA histograms using the MULTICYCLE DNA analysis package. 
tored by following DNA synthesis using [3H]thymidine incor- 
poration into DNA (Fig. 3A,B). Following synchronisation 
and removal of the drug pSVneo 1 cells move through the cell 
cycle such that DNA synthesis reaches a maximum at 3J ,  h 
decreasing at 6 h with the number of viable cells nearly doubling 
at 8 h. In contrast for Clone 1 DNA synthesis i  not completed 
at 6 h after release of drug and has still not fully declined after 
8 h such that the number of viable cells is only 50% greater than 
that found at 0 h. 
Taken together the results clearly indicate that increased 
expression of the tTgase protein in this malignant hamster 
fibrosarcoma can affect its progression through the cell cycle 
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Fig. 3. DNA synthesis and cell replication i  thymidine synchronised 
pSVneol cells (A) and (B) Clone 36. Cells were synchronised with a 
double exposure to 2 mM thymidine as described in section 2. 
(e) DNA synthesis was assessed by following the incorporation of 
[3H]thymidine and cell numbers (A) determined by microscopic 
counting. 
wild type or mutant cDNA show this characteristic t may be 
concluded that it is the GTP binding activity of the tTgase and 
not its ability to cause post-translational modification of pro- 
teins which is the cause of the effect. Our results therefore 
confirm the potential importance of this multifunctional pro- 
tein in cell growth and proliferation. It has been stated that any 
negative regulator of the cell cycle is a potential target for 
inactivation during cancer development [21]. Our findings in 
keeping with this observation since reduced levels of tTgase 
protein are generally observed in tumours [6,8,9]. This effect of 
tTgase on the cell cycle may also in part explain the reduced 
incidence of primary tumour growth observed in this hamster 
fibrosarcoma when stably transfected with the wild type tTgase 
cDNA [14]. 
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